Network Meta-Analysis of Once Weekly Selinexor-Bortezomib-Dexamethasone in Previously Treated Multiple Myeloma
**Background:** Despite the availability of new treatments, multiple myeloma (MM) is an incurable cancer with nearly all patients relapsing and undergoing multiple lines of treatment. Performing head-to-head comparisons of all treatment options is not feasible. Thus, network meta-analyses play an im...
Main Authors: | Michael Dolph, Gabriel Tremblay, Adrienne M Gilligan, Hoyee Leong |
---|---|
Format: | Article |
Language: | English |
Published: |
Columbia Data Analytics, LLC
2021-08-01
|
Series: | Journal of Health Economics and Outcomes Research |
Online Access: | https://jheor.scholasticahq.com/article/27080-network-meta-analysis-of-once-weekly-selinexor-bortezomib-dexamethasone-in-previously-treated-multiple-myeloma.pdf |
Similar Items
-
Network Meta-Analysis of Once Weekly Selinexor-Bortezomib-Dexamethasone in Previously Treated Multiple Myeloma
by: Michael Dolph, et al.
Published: (2021-08-01) -
US Budget Impact Model for Selinexor, Bortezomib, and Dexamethasone for the Treatment of Previously Treated Multiple Myeloma
by: Dolph M, et al.
Published: (2021-06-01) -
Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma
by: Maria V. Mateos, et al.
Published: (2021-04-01) -
Neuropathy and efficacy of once weekly subcutaneous bortezomib in multiple myeloma and light chain (AL) amyloidosis.
by: Surbhi Sidana, et al.
Published: (2017-01-01) -
Selinexor in relapsed/refractory multiple myeloma
by: Joshua Richter, et al.
Published: (2020-06-01)